Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
NeuroBo Pharmaceuticals, Inc. (GEMP)
|
Add to portfolio |
|
|
|
| Price: |
$1.54
| | Metrics |
| OS: |
38.4
|
M
| |
|
|
| Market cap: |
$59.2
|
M
| |
|
|
|
Net cash:
|
$28.7
|
M
| |
$0.75
|
per share
|
|
EV:
|
$30.5
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 17.3 | 12.2 | 8.8 | 0.0 | 0.0 | 0.9 | 0.0 |
| Gross profit | 0.0 | -17.3 | -12.2 | -8.8 | 0.0 | 0.0 | -0.9 | 0.0 |
| Research and development | 6.5 | 4.5 | 5.3 | 5.1 | 22.7 | 8.7 | 4.0 | 0.1 |
| General and administrative | 8.8 | 7.8 | 2.7 | 1.6 | 10.4 | 6.0 | 3.2 | 0.2 |
| EBIT | -15.3 | -29.7 | -20.2 | -15.5 | -33.1 | -14.7 | -8.1 | -0.3 |
| Pre-tax income | -15.3 | -29.7 | -21.3 | -15.5 | -33.4 | -14.6 | -9.0 | -0.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -15.3 | -29.7 | -21.3 | -15.5 | -33.4 | -15.0 | -13.0 | -0.3 |
| |
| Diluted EPS | ($0.66) | ($1.83) | ($4.08) | ($3.65) | ($3.23) | ($2.57) | ($4.54) | ($0.21) |
| Shares outstanding (diluted) | 23.1 | 16.2 | 5.2 | 4.3 | 10.3 | 5.8 | 2.9 | 1.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|